GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells

Hiroyuki Takahashi1, Takashi Nomiyama1, Yuichi Terawaki1,2, Takako Kawanami1, Yuriko Hamaguchi1, Tomoko Tanaka1, Makito Tanabe1, Dennis Bruemmer2 and Toshihiko Yanase1

1 Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, Fukuoka, Japan
2 Division of Cardiology, Department of Medicine, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, UPMC and University of Pittsburgh School of Medicine, PA, USA

Aims: Recently, incretin therapy has attracted increasing attention because of its potential use in tissue-protective therapy. Neuron-derived orphan receptor 1 (NOR1) is a nuclear orphan receptor that regulates vascular smooth muscle cell (VSMC) proliferation. In the present study, we investigated the vascular-protective effect of Exendin-4 (Ex-4), a glucagon-like peptide-1 receptor agonist, by inhibiting NOR1 expression in VSMCs.

Methods: We classified 7-week-old male 129X1/SvJ mice into control group and Ex-4 low- and high-dose-treated groups fed normal or high-fat diets, respectively. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age, followed by the evaluation of neointima formation at 12 weeks of age. To evaluate VSMC proliferation, bromodeoxyuridine incorporation assay and cell cycle distribution analysis were performed. NOR1 and cell cycle regulators were detected using immunohistochemistry, western blotting, quantitative reverse-transcription polymerase chain reaction, and luciferase assays.

Results: Ex-4 treatment reduced vascular injury-induced neointima formation compared with controls. In terms of VSMCs occupying the neointima area, VSMC numbers and NOR1-expressing proliferative cells were significantly decreased by Ex-4 in a dose-dependent manner in both diabetic and non-diabetic mice. In vitro experiments using primary cultured VSMCs revealed that Ex-4 attenuated NOR1 expression by reducing extracellular signal-regulated kinase-mitogen-activated protein kinase and cAMP-responsive element-binding protein phosphorylations. Furthermore, in the cell cycle distribution analysis, serum-induced G1–S phase entry was significantly attenuated by Ex-4 treatment of VSMCs by inhibiting the induction of S-phase kinase-associated protein 2.

Conclusion: Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation possibly by inhibiting NOR1 expression.

Key words: ERK-MAPK, GLP-1 receptor agonist, NOR1, Neointima formation, VSMC proliferation

Background

Individuals with diabetes mellitus have a greater risk of cardiovascular events than those without diabetes. Patients with diabetes frequently experience restenosis after coronary angioplasty, even after intervention with currently available drug-eluting stents. Consequently, the aim of glycemic control is not only the lowering of the blood glucose level but also improving the quality of life and mortality by preventing the occurrence and progression of vascular complications. Therefore, it is important to investigate the vascular-protective effects of anti-diabetic agents.

Incretin therapy, which includes glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, has been a focus because of its tissue-protective effects beyond lowering blood glucose levels, such as cardiovascular protection.
tion\(^4\)), anti-hepatic steatosis\(^5\), and anti-Alzheimer’s disease\(^6\). Previously, we have reported the vascular-protective effects of the GLP-1R agonist Exendin-4 (Ex-4), including the attenuation of atheroma formation in apoE-deficient mice by inhibiting NF\(\kappa\)B activation in macrophages\(^7\) and the reduction of neointima formation after vascular injury by inhibiting vascular smooth muscle cell (VSMC) proliferation\(^8\). Furthermore, we have recently demonstrated the anti-cancer effect of Ex-4 using a prostate cancer model\(^9,\)\(^10\). In addition, we reported that the DPP-4 inhibitor linagliptin attenuates neointima formation by not only incretin effects but also anti-oxidative stress effects\(^11\).

The nuclear receptor superfamily has been recognized as one of key regulators of the inflammatory response and VSMC proliferation in atherosclerosis and vascular diseases\(^12\). Although much attention is focused on peroxisome proliferator-activated receptors (PPARs)\(^13\) and liver X receptors (LXRs)\(^14\) as therapeutic targets, we have investigated the role of NR4A orphan nuclear receptors, particularly NR4A3 neuron-derived orphan receptor 1 (NOR1), in atherosclerosis and vascular diseases\(^15\). NOR1 was identified in primary cultured rat fetal forebrain cells undergoing apoptosis\(^16\). In human coronary arteries, NOR1 is expressed in VSMCs migrating into atherosclerotic lesions, but not in normal vessels, and mitogenic stimulation induces NOR1 expression via extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) and cAMP-responsive element-binding protein (CREB) phosphorylations\(^17\). NOR1 has a pivotal role in VSMC proliferation, and NOR1 deficiency reduces neointima formation after vascular injury by inhibiting G1–S phase entry of cell cycle progression in VSMCs, as we reported previously\(^18,\)\(^19\). However, currently, there are no reports that have elucidated the interaction between GLP-1 and NOR1 in VSMCs. In the present study, we demonstrate that Ex-4 attenuates NOR1 expression both \textit{in vivo} and \textit{in vitro} in VSMCs.

## Methods

### Animals

The study protocol was reviewed and approved by the Animal Care and Use Committee of Fukuoka University. Six-week-old male 129X1/SvJ mice were purchased from Japan SLC, Inc. (Sizuoka, Japan). All mice were housed in a polycarbonate cage with a wooden chip mat on the floor, and water was available \textit{ad libitum}. All mice were fed normal chow (20% protein, 70% carbohydrate, and 10% fat; D12450B, Research Diet, New Brunswick, NJ). The animal room was kept in a 12-h light/dark cycle at a constant temperature (22°C ± 1°C) and relative humidity of 55% ± 5% throughout the experimental period. Mice were divided into the saline-control (\(n = 9\)) group, Ex-4 low-dose (300 pmol/kg body weight/day, \(n = 10\))-treated group, and Ex-4 high-dose (24 nmol/kg body weight/day, \(n = 10\))-treated group. At 7 weeks of age, a miniosmotic pump (ALZEST, model 1004; DURECT, Cupertino, CA) was implanted under the skin of the back of each mouse after local anesthesia. Saline or Ex-4 (Sigma-Aldrich, Tokyo) was infused via the osmotic pump that continuously delivered the solution for up to 4 weeks. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age, followed by the evaluation of neointimal formation at 12 weeks of age.

### Animals Fed High-Fat Diet

Seven-week-old male 129X1/SvJ mice were fed high-fat diet (20% protein, 20% carbohydrate, and 60% fat, D12492, Research Diet) and divided into the saline-control (\(n = 5\)) group, Ex-4 low-dose (300 pmol/kg body weight/day, \(n = 5\))-treated group, and Ex-4 high-dose (24 nmol/kg body weight/day, \(n = 5\))-treated group. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age. Mice were euthanized at 12 weeks of age and femoral arteries were isolated for tissue analysis.

### Guidewire-Induced Endothelial Denudation Injury

Mouse femoral artery endothelial denudation injuries were established, as we previously reported\(^8,\)\(^11,\)\(^18\), in 129X1/SvJ mice treated as control (saline, \(n = 9\)), Ex-4 low-dose (300 pmol/kg/day, \(n = 10\)), and Ex-4 high-dose (24 nmol/kg/day, \(n = 10\)) groups at 8 weeks of age, as described previously\(^8\). Briefly, endovascular injuries were induced by four passages of a 0.25-mm SilverSpeed-10 hydrophilic guidewire (Micro Therapeutics Inc., Irvine, CA, USA) into the left femoral artery. Mice were euthanized at 4 weeks after injury, and femoral arteries were isolated for tissue analysis.

### Tissue Preparation and Morphometry

Following sacrifice, mice were perfused via a cannula in the left ventricle with phosphate-buffered saline for 5 min, followed by 4% paraformaldehyde for 30 min at 100 cm H2O. The femoral arteries were embedded in paraffin, cut into 5-µm sections, and prepared for Elastica van Gieson and immunofluorescence staining. Serial sections of the 0.5-mm proximal region from the incision site of the wire insertion were evaluated using Elastica van Gieson stain kit (ab150667, Abcam, Cambridge, UK) to visualize the internal elastic lamina, as described previously\(^11\). Specimens were viewed under a microscope (BZ9000; Keyence, Tokyo, Japan) connected to a computer. Intimal and me-
Alexa Fluor 647 goat anti-rabbit IgG (A21246, Life technologies), and sections analyzed for PCNA were subsequently incubated with Alexa Fluor 488 donkey anti-goat IgG (A11055, Life technologies). Sections were counterstained with DAPI and visualized using confocal microscopy.

**Insulin Measurements**

Insulin concentrations in mouse serum were measured using Ultra-Sensitive Mouse Insulin ELISA Kit (Morinaga Institute of Biological Science, Inc. Kanagawa, Japan), according to the manufacturer’s protocol.

**Cell Culture**

Human aortic smooth muscle cells were purchased from Lonza (Allendale, NJ) and maintained in dial areas were measured by computerized morphometry using BZ-II analyzer software (Keyence, Tokyo, Japan). Intimal hyperplasia was defined as neointimal layer formation medial to the internal elastic lamina. The medial area represents the area between external and internal elastic laminae. The intima-to-media ratio was calculated as the intimal area divided by the media area, as described previously.

**Immunohistochemistry**

Paraffin sections were incubated with a Cy-3-conjugated α-smooth muscle actin antibody (C6198, Sigma-Aldrich). Serial sections were incubated with anti-NOR1 (HPA043360, Sigma-Aldrich) and anti-PCNA (sc-9857; Santa Cruz, CA) antibodies. Sections analyzed for NOR1 were subsequently incubated with Alexa Fluor 647 goat anti-rabbit IgG (A21246, Life technologies), and sections analyzed for PCNA were subsequently incubated with Alexa Fluor 488 donkey anti-goat IgG (A11055, Life technologies). Sections were counterstained with DAPI and visualized using confocal microscopy.

**Insulin Measurements**

Insulin concentrations in mouse serum were measured using Ultra-Sensitive Mouse Insulin ELISA Kit (Morinaga Institute of Biological Science, Inc. Kanagawa, Japan), according to the manufacturer’s protocol.

**Cell Culture**

Human aortic smooth muscle cells were purchased from Lonza (Allendale, NJ) and maintained in
Table 1. Neointima formation in exendin-4 (Ex-4)-treated mice at 12 weeks of age following guidewire-induced endothelial denudation injury.

|          | Control       | Ex-4 Low dose | Ex-4 High dose |
|----------|---------------|---------------|----------------|
| Intima (µm²) | 36511.8 ± 9621.7 | 23830.0 ± 4583.6 | 14284.1 ± 3801.2 |
| Media (µm²)  | 16049.2 ± 2385.1  | 13948.9 ± 1235.0 | 10338.5 ± 985.9 |
| I/M ratio   | 2.12 ± 0.37    | 1.70 ± 0.42    | 1.28 ± 0.31    |

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM. P-values refer to comparisons with the control.

Table 2. Characteristics of exendin-4 (Ex-4)-treated mice at 12 weeks of age following guidewire-induced endothelial denudation injury.

|          | Control       | Ex-4 Low dose | Ex-4 High dose |
|----------|---------------|---------------|----------------|
| Body weight (g) | 28.1 ± 0.6    | 28.5 ± 0.3    | 26.3 ± 0.5*## |
| Plasma glucose (mg/dl) | 150.4 ± 4.0   | 150.0 ± 3.4   | 137.1 ± 8.2   |
| Serum insulin (ng/ml) | 0.64 ± 0.07   | 0.73 ± 0.08   | 0.47 ± 0.09   |

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM. *p<0.05 compared with the control. ##p<0.01 compared with low-dose Ex-4.

Western Blot Analysis

Western blotting was performed, as described previously. The following primary antibodies were used: NOR1 (TA804872; ORIGÈNE), phospho-p44/42 MAPK (Thr202/Tyr204) (#9101; Cell Signaling), p44/42 MAPK (#9102; Cell Signaling), phospho-CREB (Ser133) (#9198; Cell Signaling), CREB (#9197; Cell Signaling), phospho-Akt (Ser473) (#4068; Cell Signaling), Protein kinase B (Akt) (#9272; Cell Signaling), phospho-mTOR (Ser2448) (#2983; Cell Signaling), mTOR (#2983; Cell Signaling), p27 Kip1 (#3686; Cell Signaling), and GAPDH (sc-20357; Santa Cruz).

Reverse Transcription (RT) and Quantitative Real-Time PCR

RT and quantitative real-time PCR were performed, as described previously. mRNA from human aortic SMCs was isolated using RNeasy Mini Kits (Qiagen, Venlo, the Netherlands) and reverse transcribed into cDNA. PCRs were performed using Light Cycler 2.0 (Roche, Basel, Switzerland) and SYBR Premix Ex Taq™ (Takara, Otsu, Japan). Each sample was analyzed in triplicate and normalized against TATA binding protein (TBP) mRNA expression. The following primer sequences were used: human TBP, 5′-TGCT-GCGGTAATCATGAGGATA-3′ (forward), 5′-TGAGTCTCAAGACGGTTCAGGA-3′ (reverse); human NOR1, 5′-CCCCTCAGGGTTCCAGGTAT-3′ (forward), 5′-ATTTGGTACACGCAGGAAGG-3′ (reverse); human Skp2, 5′-ACACTGCAAAAGCCCAAGTCGTTG-3′ (forward), 5′-TGCAGAATGAAGGCAAGGGCC-3′ (reverse).
Human aortic SMCs were seeded in 60-mm dishes at a density of $1 \times 10^5$ cells/ml. Cells were grown to 60% – 70% confluence, serum-deprived for 36 h, pretreated with 10 nM Ex-4 or saline for 12 h, stimulated with FBS for 30 h. Cell cycle analysis was performed using Cycletest™ Plus DNA reagent kit (BD Biosciences), as per the manufacturer’s instructions, and a BD FACSVerse (BD Biosciences, Franklin Lakes, NJ, USA). FlowJo (Tree Star, Inc., OR, USA) was used to analyze the flow cytometry data.

**Statistical Analysis**

Results are expressed as mean ± SEM. All statistical analyses were performed using GraphPad Prism.
all groups, and neointima formation was evaluated at 12 weeks of age. Endothelial denudation injury in control mice resulted in considerable neointima formation. As depicted in Fig. 1A, elastic staining revealed the reduction of neointima formation after vascular injury. Quantitative analysis by measuring squares of the intima, media, and intima-to-media (I/M) ratio suggested that Ex-4 reduced neointima formation after vascular injury in a dose-dependent manner (Fig. 1B). However, statistical significances were not achieved (Table 1). As shown in Table 2, although high-dose Ex-4 significantly decreased mouse body weight, the blood glucose level and serum insulin concentration

Fig. 3. FBS-induced NOR1 expression is suppressed by Ex-4 pretreatment in vitro.

(A) Serum-deprived human aortic SMCs were stimulated with 10% FBS with 0–10 nM Ex-4 pretreatment. NOR1 protein expression was analyzed at 6 h after FBS stimulation by western blotting. (B) FBS-induced NOR1 mRNA expression was analyzed at 2 h after FBS stimulation with 0–10 nM Ex-4 pretreatment by qRT-PCR. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. *P<0.05 vs. FBS(+) 0 nM Ex-4, **P<0.01 vs. FBS(+) 0 nM Ex-4. (C) Rat aortic SMCs were transiently transfected with 1.7 kb NOR1 promoter constructs. Serum-deprived cells were pretreated with or without 10 nM Ex-4 and then stimulated with 10% FBS for 12 h. Following stimulation, cells were harvested and luciferase activities were analyzed. Statistical significance was calculated using unpaired t-tests. Data are mean ± SEM. *P<0.05 vs. Control FBS(–). (D) Serum-deprived SMCs were treated with 10 nM Ex-4 or PBS and pretreated for 30 min with or without 100 nM Exendin (9-39) or 10 µM PKI and subsequently stimulated with FBS at a final concentration of 10%. After 2 h of stimulation, NOR1 mRNA expression was determined. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. *P<0.05 vs. FBS(–) control, **P<0.05 vs. FBS(+) Exendin (9-39).

Results

Exendin-4 Attenuates Neointima Formation After Vascular Injury in Non-Diabetic Mice

129X1/SvJ mice were treated with the control (saline), low-dose Ex-4, or high-dose Ex-4 from 7 to 12 weeks of age. Mouse femoral artery endothelial denudation injuries were established at 8 weeks of age in software (version 7.0; GraphPad Software, SD, USA). Unpaired t-tests and one- or two-way ANOVA were performed for statistical analysis, as appropriate. P-values <0.05 were considered statistically significant.
were not changed by Ex-4 treatment because the mice were not diabetic, suggesting that the reduction of neointima formation by Ex-4 was independent of the Ex-4 effect on glucose metabolism.

**Exendin-4 Decreases VSMC Proliferation and NOR1 Expression in the Neointima**

To confirm that cells occupying the neointima after vascular injury were VSMCs, we next performed immunohistochemistry using VSMC marker α-smooth muscle cell actin. As depicted in *Fig. 2*, all cells located in the neointima were VSMC (*Fig. 2A*) in all groups. To examine whether Ex-4 decreased the number of cells occupying neointima formation, we counted cells in the intima and media areas. As shown in *Fig. 2B*, Ex-4 decreased the cell number in the neointima and the I/M ratio in a dose-dependent manner. Compared with the control, significant reduction in the cell number was achieved in the high-dose Ex-4 group. To further examine whether Ex-4 decreased NOR1 expression in migrating VSMCs after vascular injury, we next conducted NOR1 immunohistochemistry using injured mouse vessels. As depicted in *Fig. 2C*, profound NOR1 expression with nuclear localization was detected in non-Ex-4-treated control vessels. However, NOR1 expression was dramatically decreased in Ex-4-treated mouse vessels. Finding NOR1-positive cells in the neointima suggested that Ex-4 significantly and...
mouse VSMCs, NOR1 expression was also negligible in serum-deprived quiescent human VSMCs, and serum stimulation dramatically and promptly induced NOR1 protein expression. Interestingly, after pretreatment with Ex-4, serum-induced NOR1 expression was significantly decreased in a dose-dependent manner. To elucidate whether Ex-4 decreased NOR1 expression by inhibiting NOR1 promoter activity, we next conducted a luciferase assay using NOR1 promoter-Luc construct transfected into rat VSMCs. As shown in Fig. 3C, serum-induced NOR1 protein expression was significantly reduced by 10 nM Ex-4 pretreatment, suggesting that Ex-4 decreased NOR1 expression in vivo.

**Exendin-4 Decreases Serum-Induced NOR1 Expression Via GLP-1R**

Next, we examined whether Ex-4 inhibited NOR1 expression *in vitro* using primary cultured VSMCs. Compatible with our previous reports using rat and mouse VSMCs, NOR1 expression was also negligible in serum-deprived quiescent human VSMCs, and serum stimulation dramatically and promptly induced NOR1 protein (Fig. 3A) and mRNA (Fig. 3B) expression. Interestingly, after pretreatment with Ex-4, serum-induced NOR1 expression was significantly decreased in a dose-dependent manner (Fig. 3A, B). To elucidate whether Ex-4 decreased NOR1 expression by inhibiting NOR1 promoter activity, we next conducted a luciferase assay using NOR1 promoter-Luc construct transfected into rat VSMCs. As shown in Fig. 3C, serum-induced NOR1 promoter activity was significantly reduced by 10 nM Ex-4 pretreatment, suggesting that Ex-4 decreased NOR1 expres-
Exendin-4 Inhibits Serum-Induced ERK-MAPK and CREB Phosphorylations

In our previous report, mitogenic stimulation induced NOR1 expression via ERK-MAPK and CREB phosphorylations\(^{17}\). Next, we examined the effect of Ex-4 on ERK-MAPK and CREB phosphorylations in human VSMCs by western blotting. As shown in Fig. 4A, pretreatment with 10 nM Ex-4 significantly decreased serum-induced phosphorylation of ERK-MAPK. Furthermore, serum-induced CREB phosphorylation was decreased by Ex-4 pretreatment (Fig. 4B). These data suggest that Ex-4 decreased NOR1 expression via the inhibition of ERK-MAPK-CREB signals in VSMCs. In addition, we examined other VSMC growth signals, protein kinase B (Akt) and mammalian target of rapamycin (mTOR). As shown in Fig. 4C, Ex-4 did not attenuate serum-induced Akt phosphorylation. However, small but significant attenuation of serum-induced mTOR phosphorylation was observed after Ex-4 treatment (Fig. 4C).

Exendin-4 Attenuates Cell Cycle Progression in VSMCs

Because NOR1 regulates VSMC proliferation by accelerating G1–S phase during cell cycle progression, as we reported previously\(^{18}\), we next examined whether Ex-4 attenuates cell cycle progression in human VSMCs. As shown in Fig. 5, G1–S phase and G2/M phase were induced by serum stimulation in human VSMCs. Furthermore, 10 nM Ex-4 pretreatment significantly attenuated cell cycle progression induced by serum (Table 3), suggesting that Ex-4 inhibits VSMC proliferation by attenuating cell cycle progression. Next, we examined whether Ex-4 regulated cell cycle regulators. As shown in Fig. 4C, serum-induced degradation of p27 Kip, a major negative regulator of G1–S phase entry, was significantly inhibited by Ex-4 treatment. In addition, S-phase kinase-associated protein 2 (Skp2), which is the ubiquitin ligase of p27 Kip, was induced by serum stimulation and resulted in p27 kip degradation. Interestingly, Ex-4 significantly decreased Skp2 gene expression after serum stimulation (Fig. 5D).

Exendin-4 Attenuates Neointima Formation After Vascular Injury in Diabetic Mice

Because Ex-4 is used as a medication for patients with type 2 diabetes mellitus (T2DM), we next examined whether Ex-4 decreased neointima formation after vascular injury in mice fed high-fat diet, a model for insulin-resistant T2DM. As depicted in Fig. 6A, elastic staining revealed the reduction of neointima formation after vascular injury. Quantitative analysis by measuring squares of the intima, media, and I/M ratio suggested that Ex-4 reduced neointima formation after vascular injury in a dose-dependent manner (Fig. 6B). However, statistical significance was not observed (Table 4). As shown in Table 5, body weight and the plasma glucose level were significantly decreased by Ex-4 in a dose-dependent manner, suggesting that Ex-4 affected glucose metabolism.

Following experiments using non-diabetic normal mice, we counted cells in the neointima and media areas. As shown in Fig. 7A, the neointima was completely occupied by VSMCs, and the cell number in the neointima and I/M ratio were decreased dose-dependently, although statistical significance was not observed. For further investigation, we performed immunohistochemistry of NOR1 and PCNA. As shown in Fig. 7C, Ex-4 decreased NOR1 expression and PCNA-positive proliferating cells. Furthermore, cell counting revealed that the Ex-4-induced reductions of

| Table 3. Cell cycle distribution of human vascular smooth muscle cells with or without exendin-4 (Ex-4) treatment |
|--------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                                   | Control FBS(−)  | Ex-4 FBS(−)     | Control FBS(+)  | Ex-4 FBS(+)     |
| G0/G1 (%)                                         | 91.2 ± 0.5      | 91.6 ± 1.3      | 70.3 ± 2.8      | 77.5 ± 2.7      |
| S (%)                                             | 5.6 ± 0.3       | 3.9 ± 0.2       | 23.7 ± 1.4      | 16.5 ± 2.5*     |
| G2/M (%)                                          | 4.9 ± 0.5       | 5.8 ± 0.2       | 13.5 ± 0.7      | 9.4 ± 1.3*      |

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM. FBS, fetal bovine serum.

\( ^* P<0.05 \) compared with the Control FBS(+).
expression, resulting in inhibition of cell cycle progression. As we reported previously\(^7\), \(^8\), the direct vascular-protective effect of incretin has been a recent focus. Reports from other groups confirmed the hypothesis that incretins, particularly GLP-1, may have direct anti-atherosclerotic and vascular-protective effects independent of their glucose-lowering effect\(^20\), \(^21\). Furthermore, current evidence based on large scale clinical trials in patients with type 2 diabetes using GLP-1R agonists suggest vascular-protective effects of GLP-1 in animal models as well as patients with type 2 diabetes\(^22\), \(^23\). VSMC proliferation contributes to not only primary atherosclerotic lesions but also vascular stenosis after vascular injury and coronary angioplasty. In addition, several pathological backgrounds in the dia-

**Discussion**

The present study suggested that GLP-1R agonist Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation in vivo, even in diabetic model mice.
NOR1 phosphorylation by DNA-dependent protein kinase reportedly modulates VSMC proliferation. Despite several known regulation mechanisms of NOR1 expression and its activation, there has been no report suggesting NOR1 regulation in VSMCs by clinical medications, such as anti-hypertensive drugs, anti-diabetic agents, and anticoagulants. This is the first report suggesting that an anti-diabetic agent and a GLP-1R agonist attenuates NOR1 expression in VSMCs. In our previous reports using mouse VSMCs, we investigated two main targets of NOR1 that accelerate VSMC proliferation: Cyclin D1 and Skp2. In the present study using human VSMCs, Cyclin D1 expression was not changed by Ex-4-induced NOR1 reduction (data not shown). However, Skp2 gene expression was significantly decreased, resulting in the upregulation of p27 Kip protein expression and attenuation of cell cycle progression. These data suggest that the main target of NOR1 related to cell cycle progression is Skp2 in human VSMCs.

In the present study, we found that Ex-4 inhibited serum-induced ERK-MAPK phosphorylation. Interestingly, we previously reported the same Ex-4 effect via epigenetic modification and microRNA-638 expression. Furthermore, NOR1 phosphorylation by DNA-dependent protein kinase reportedly modulates VSMC proliferation. Despite several known regulation mechanisms of NOR1 expression and its activation, there has been no report suggesting NOR1 regulation in VSMCs by clinical medications, such as anti-hypertensive drugs, anti-diabetic agents, and anticoagulants. This is the first report suggesting that an anti-diabetic agent and a GLP-1R agonist attenuates NOR1 expression in VSMCs. In our previous reports using mouse VSMCs, we investigated two main targets of NOR1 that accelerate VSMC proliferation: Cyclin D1 and Skp2. In the present study using human VSMCs, Cyclin D1 expression was not changed by Ex-4-induced NOR1 reduction (data not shown). However, Skp2 gene expression was significantly decreased, resulting in the upregulation of p27 Kip protein expression and attenuation of cell cycle progression. These data suggest that the main target of NOR1 related to cell cycle progression is Skp2 in human VSMCs.

**Table 4.** Neointima formation in exendin-4 (Ex-4)-treated mice fed a high-fat diet at 12 weeks of age following guidewire-induced endothelial denudation injury.

|                | HFD Control | HFD + Ex-4 Low dose | HFD + Ex-4 High dose |
|----------------|-------------|---------------------|----------------------|
| Intima (µm²)   | 38212.6 ± 10921.1 | 32594.0 ± 7907.7 (P=0.91) | 18532.2 ± 6446.3 (P=0.35) |
| Media (µm²)    | 12079.2 ± 1549.1 | 11684.0 ± 1615.7 (P=0.90) | 11072.0 ± 1235.9 (P=0.96) |
| I/M ratio      | 2.78 ± 0.67 | 2.66 ± 0.57 (P=0.99) | 2.66 ± 0.57 (P=0.99) |

Data are expressed as the mean ± SEM. P-values refer to comparisons with the control.

**Table 5.** Characteristics of exendin-4 (Ex-4)-treated mice fed a high-fat diet at 12 weeks of age following guidewire-induced endothelial denudation injury.

|                | HFD Control | HFD + Ex-4 Low dose | HFD + Ex-4 High dose |
|----------------|-------------|---------------------|----------------------|
| Body weight (g) | 29.1 ± 0.4 | 28.9 ± 0.5 | 25.7 ± 0.8* | 25.7 ± 0.8* |
| Plasma glucose (mg/dl) | 158.2 ± 4.2 | 126.4 ± 12.3 | 119.4 ± 4.2* | 119.4 ± 4.2* |
| Serum insulin (ng/ml) | 1.07 ± 0.21 | 0.60 ± 0.14 | 0.56 ± 0.09 | 0.56 ± 0.09 |

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM.

*P < 0.05 compared with the control. **P < 0.05 compared with low-dose Ex-4.
randomized control trial using Exenatide, the EXSCEL study, could not demonstrate significant reduction compared with the placebo control\(^{35}\), although other GLP-1R agonists did improve cardiovascular outcome\(^{22, 23}\). The EXSCEL study has a shorter study period and higher baseline HbA1c than the LEADER trial using liraglutide\(^{22}\) (3.8 years vs. 3.2 years and 8.0% vs. 8.7%, respectively). In addition, sulfonylureas and insulin use were profoundly increased in the placebo group of the LEADER trial, although GLP-R agonists, sodium-glucose cotransporter 2 inhibitors, and DPP-4 inhibitors use were increased in the placebo group of the EXSCEL trial\(^{35}\). These clinical differences may contribute to the different cardiovascular outcomes between the LEADER trial and EXSCEL study. In fact, the low dose of Ex-4 in the present study is the pharmacological dose, as discussed in our previous studies\(^{7, 8}\).

In the present study, all our experiments were conducted using Ex-4 as a GLP-1R agonist, which is clinically available as Exenatide. Although the present study and our previous studies\(^{7, 8}\) demonstrated the vascular-protective effect of Ex-4, a recent large scale randomized control trial using Exenatide, the EXSCEL study, could not demonstrate significant reduction compared with the placebo control\(^{35}\), although other GLP-1R agonists did improve cardiovascular outcome\(^{22, 23}\). The EXSCEL study has a shorter study period and higher baseline HbA1c than the LEADER trial using liraglutide\(^{22}\) (3.8 years vs. 3.2 years and 8.0% vs. 8.7%, respectively). In addition, sulfonylureas and insulin use were profoundly increased in the placebo group of the LEADER trial, although GLP-R agonists, sodium-glucose cotransporter 2 inhibitors, and DPP-4 inhibitors use were increased in the placebo group of the EXSCEL trial\(^{35}\). These clinical differences may contribute to the different cardiovascular outcomes between the LEADER trial and EXSCEL study. In fact, the low dose of Ex-4 in the present study is the pharmacological dose, as discussed in our previous studies\(^{7, 8}\).
reports, suggesting that some beneficial clinical cardiovascular effect could be expected from the present study. However, different individual effects on cardiovascular systems by GLP-1R agonists are also suggested. Further clinical trials and basic experiments are required.

**Conclusion**

Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation possibly by inhibiting NOR1 and Skp2 expression. In addition, Ex-4 attenuates ERK-MAPK and CREB phosphorylations as well as G1-S phase entry during cell cycle progression in VSMCs. The reduction of NOR1 expression could be key in preventing cardiovascular events and atherosclerosis in patients with type 2 diabetes using incretin therapy.

**List of Abbreviations**

Akt, Protein kinase B; CREB, cAMP-responsive element-binding protein; DPP-4, dipeptidyl peptidase-4; ERK-MAPK, extracellular signal-regulated kinase-mitogen-activated protein kinase; Ex-4, exendin-4; Ex9-39, Exendin 9-39; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor; I/M, intima-media; NOR1, neuron-derived orphan receptor 1; PKA, protein kinase A; PPAR, peroxisome proliferator-activated receptor; LXR, liver X receptor; VSMCs, vascular smooth muscle cells; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; Skp2, S-phase kinase-associated protein 2.

**Competing Interests**

The present study was supported by a grant from Novartis Pharma K.K. and MSD K.K. to TN. The other authors have no competing interests.

**Authors’ Contributions**

HT performed experiments and wrote the manuscript; TN performed experiments, wrote the manuscript, and conceived the research hypothesis; TK and YH performed the experiments; YT, TT, MT, and DB reviewed and edited the manuscript and assisted in patient recruitment; and TY assisted in the conception of the research hypothesis and reviewed and edited the manuscript. All authors have read and approved the final manuscript. TN is the guarantor of this work, has full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of data analysis.

**Acknowledgements**

We thank Dr. Naganari Ohkura (Osaka University, Osaka, Japan) for providing NOR1 promoter constructs. We also thank Mitchell Arico from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

**References**

1) Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Eng J Med 1998, 339: 229-234
2) Scheen AJ, Warzee F: Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care 2004, 27: 1840-1841
3) Richard E. Pratley, Matthew Gilbert: Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud 2008, 5: 73-94
4) Pujadas G, Drucker DJ: Vascular biology of glucagon receptor superfamily peptide: Mechanistic and clinical relevance. Endocr Rev 2016, 37: 554-583
5) Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43: 173-181
6) Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG: An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Aβ oligomers. J Clin Invest 2012, 122: 1339-1353
7) Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59: 1030-1037
8) Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa AT, Kawamori R, Fujitani Y, Hirose T, Watada T: Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43: 1339-1353
9) Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59: 1030-1037
10) Tsutsumi Y, Nomiyama T, Kawanami T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa AT, Kawamori R, Fujitani Y, Hirose T, Watada T: Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. PLoS ONE 2010, 5: e11051
11) Tsutsumi Y, Nomiyama T, Kawanami T, Hanaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Hidetaka Morinaga, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T: Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. PLoS ONE 2010, 5: e11051
22) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Hirata Y, Kurobe H, Nishio C, Tanaka T, Hedin U, Ruzaev A: Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of artery injury. J Vasc Res 2015, 52: 41-52

23) Zhao L, Li AQ, Zhou TF, Zhang MQ, Qin XM: Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. Am J Physiol Cell Physiol 2014, 307: C1130-C1141

24) Bruegger D: C-peptide in insulinresistance and vascular complications: teaching an old dog new tricks. Circ Res 2006, 99: 1149-1151

25) Eriksson L, Saxelin R, Rohl S, Roy J, Caidahl K, Nyström T, Ruzaev A: Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of artery injury. J Vasc Res 2015, 52: 41-52

26) Zhao L, Li AQ, Zhou TF, Zhang MQ, Qin XM: Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. Am J Physiol Cell Physiol 2014, 307: C1130-C1141

27) Morales PE, Torres G, Sotomayor-Flores C, Pena-Oyarzun D, Pivera-Mejias P, Paredes F, Chiong M: GLP-1 Promotes mitochondrial metabolism in vascular smooth muscle cells by enhancing endothelial reticulum-mitochondria cpoupling. Biochem Biophys Res Commun 2014, 446: 410-416

28) Yang G, Lei Y, Inoue A, Piao L, Hu L, Jiang H, Sasaki T, Wu H, Xu W, Yu C, Zhao G, Ogasawara S, Okumura K, Kuzuya M, Cheng XW: Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress. Atherosclerosis 2017, 264: 1-10

29) Piao L, Zhao G, Zhu E, Inoue A, Shibata R, Lei Y, Hu L, Yu C, Yang G, Wu H, Xu W, Yu C, Zhao G, Ogasawara S, Okumura K, Ouchi N, Murohara T, Kuzuya M, Chen XW: Chronic phychological stress accelerates vascular senescence and impairs isch-emia-induced neovascularization: the role of dipeptidyl peptidase-4/glucagon-loke peptide-1-adiponectin axis. J Am Heart Assoc 2017, 6: e006421

30) Zhao Y, Nomiyama T, Findeisen HM, Qing H, Aono J, Jones KL, Heywood EB, Bruemmer D: Deficiency of the NR4A orphan-derived orphan receptor-1 attenuates neointima formation after vascular injury. Circulation 2009, 119: 577-586

31) Gizard F, Zhao Y, Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Conneely OM, Bruemmer D: The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem 2006, 281: 33467-33476

32) Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Conneely OM, Bruemmer D: Cloning of a novel thyroid/steroid receptor superfamily gene from cultured rat neuronal cells. Biocem Biophys Res Commun 1994, 205: 1959-1965

33) Li P, Liu Y, Yi B, Wang G, You X, Zhao X, Summer R, Zhao Y, Nomiyama T, Findeisen HM, Qing H, Aono J, Jones KL, Heywood EB, Bruemmer D: Deficiency of the NR4A orphan nuclear receptor NOR1 attenuates neointima formation after vascular injury. Circulation 2009, 119: 577-586

34) Ordelheide AM, Gerst F, Rothfuss O, Heni M, Haas C, Meier JJ: GLP-1 receptor agonists for individualized treat-ment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8: 728-742

35) Orelheide AM, Gerst F, Rothfuss O, Heni M, Haas C, Thielker I, Herzberg-Schafer S, Bohn A, Machicao F, Ullrich S, Stefan N, Fritsche A, Haring HU, Staiger H: Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion. Mol Metab 2013, 2: 243-255
35) Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Igbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group: Effect of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017, 377: 1228-1239

36) Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, Horikawa T, Yoshinaga Y, Yamashita S, Tanaka T, Terawaki Y, Tanaba M, Nabeshima K, Iwasaki A, Yanase T: Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-κB activation. Endocrinology 2017, 158: 4218-4232

37) Lim S, Kim KM, Nauck MA. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab 2018, 29: 238-248